Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 22INDUSTRY 21OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 90Vincristine 83Doxorubicin 69Prednisone 66Cytarabine 59Methotrexate 58Rituximab 49Etoposide 43Radiotherapy 41Dexamethasone 41Filgrastim 39Leucovorin 27Mercaptopurine 26Granulocyte Colony-Stimulating Factor 26pegaspargase 22Calcium Dobesilate 22Daunorubicin 21Asparaginase 20merphos 19Specimen Handling 18Thioguanine 17Hydrocortisone 16Bleomycin 16Peripheral Blood Stem Cell Transplantation 14Vinblastine 13Gene Expression Profiling 13Methylprednisolone 12Ifosfamide 12Gemcitabine 12dexamethasone acetate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Injections × Lymphoid × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡